Oxford BioDynamics PLC (AIM:OBD) shares soared in early deals, as it unveiled a new collaboration with Google Cloud.
In the project, they plan to develop and deploy Oxford BioDynamics’ EpiSwitch analytical framework on the cloud.
Google Cloud will provide computing resources to help the company scale its AI-powered 3D genomic analytics. The tools will be available in a secure and globally accessible environment for its pharma and biotech partners.
"Working with Google Cloud allows OBD to rapidly scale its analytical capabilities, bringing it closer to delivering precision 3D genomics insights in real time,” executive chair Iain Ross said in a statement.
He added: “The formation of this collaboration with Google Cloud only serves to validate this view.
“We are excited to develop a powerful and interoperable platform that aligns with the future of cloud-native biomedical research.
“Google Cloud's global infrastructure allows us to share insights faster, collaborate more easily with our partners, and bring our predictive genomic tools into clinics and labs around the world - at scale."
In London, Oxford BioDynamics shares gained 13.5% in early exchanges, to change hands at 0.43p – valuing the business at around £8.5 million.